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ARTICLE
Crystal structure of the catalytic domain of HIV-1
restriction factor APOBEC3G in complex with
ssDNA
Atanu Maiti 1, Wazo Myint 1, Tapan Kanai 1, Krista Delviks-Frankenberry 2, Christina Sierra Rodriguez1,
Vinay K. Pathak2, Celia A. Schiffer 3 & Hiroshi Matsuo 1
The human APOBEC3G protein is a cytidine deaminase that generates cytidine to deoxy-
uridine mutations in single-stranded DNA (ssDNA), and capable of restricting replication of
HIV-1 by generating mutations in viral genome. The mechanism by which APOBEC3G spe-
ciﬁcally deaminates 5′-CC motifs has remained elusive since structural studies have been
hampered due to apparently weak ssDNA binding of the catalytic domain of APOBEC3G. We
overcame the problem by generating a highly active variant with higher ssDNA afﬁnity. Here,
we present the crystal structure of this variant complexed with a ssDNA substrate at 1.86 Å
resolution. This structure reveals atomic-level interactions by which APOBEC3G recognizes a
functionally-relevant 5′-TCCCA sequence. This complex also reveals a key role of W211 in
substrate recognition, implicating a similar recognition in activation-induced cytidine dea-
minase (AID) with a conserved tryptophan.
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Human APOBEC (“apolipoprotein B mRNA editingenzyme, catalytic polypeptide”) proteins are single-stranded DNA (ssDNA) cytidine deaminases that
catalyze the Zn-dependent deamination of a deoxy-cytidine,
generating deoxy-uridine1. The APOBEC family includes APO-
BEC1, APOBEC2, APOBEC3, APOBEC4, and activation-induced
cytidine deaminase (AID)1. Among them, APOBEC3 proteins are
genetically expanded in humans in response to the evolution of
pathogens2,3. As a result of this expansion, humans contain seven
APOBEC3 proteins (APOBEC3A, 3B, 3C, 3D, 3F, 3G, and 3H),
which are all encoded on chromosome 224. APOBEC3G (A3G)
restricts human immunodeﬁciency virus type 1 (HIV-1)5–9, a
ﬁnding that prompted extensive studies of APOBEC3 protein
restriction of retroviruses and retrotransposons10–13. Of the
seven human APOBEC3 proteins, A3D, A3F, A3G, and A3H can
restrict HIV-1, and hypermutation of the virus genomes by their
deamination activity is the primary mechanism by which these
A3 proteins restrict HIV-110–13. The APOBEC3 proteins catalyze
the deamination of deoxy-cytidine introducing C-to-U mod-
iﬁcations in newly synthesized (−)DNA strands of the virus
genome, which results in G-to-A mutations in (+)DNA as U is
used as a template during (+)DNA strand synthesis14. Although,
there are many reports of deaminase-independent HIV restriction
by APOBEC3 proteins, the signiﬁcance of deaminase-
independent mechanisms remains elusive and requires further
study15.
HIV-1 has developed a mechanism against APOBEC3 proteins
by using one of its accessory proteins, namely viral infectivity
factor or Vif16. Vif physically interacts with HIV-relevant APO-
BEC3 proteins, and assembles host cellular proteins including an
E3 ubiquitin ligase to trigger degradation of the APOBEC3 pro-
teins through the ubiquitin–proteasome pathway16. For A3D,
A3F, and A3G, which contain two Zn2+-binding motifs/domains,
the catalytically inactive N-terminal domain (NTD) binds Vif as
well as RNA, DNA, and other viral proteins17. The C-terminal
domain (CTD) of these APOBEC3 proteins is catalytically active,
containing Zn2+-binding motif HxE-x23–28-C-x2–4-C. The cata-
lytic mechanism of cytosine/cytidine deamination has been stu-
died biochemically and structurally using deaminases from
Escherichia coli and yeast. Brieﬂy, the hydroxide ion generated
from a water molecule chelating Zn2+ attacks the C4 atom of
cytosine, then the hydrogen is transferred to the carboxylate
group of glutamic acid from the Zn2+-binding motif; this
hydrogen is ultimately transferred to the product ammonia18–20.
Although all APOBEC3 proteins deaminate cytidines in
ssDNA, they show differences in preferred hotspot sequences as
5ʹ-CC for A3G and 5ʹ-TC for other A3s (A3A can deaminate 5ʹ-
CC albeit to a lesser extent)21. A3G’s deamination mechanism
may be more complicated than that of other A3 proteins because
several groups have reported that A3G deaminates 5ʹ-CC hot-
spots processively from the 3ʹ-end to the 5ʹ-end of ssDNA22.
Three-dimensional structures of APOBEC proteins have
emerged in the last 10 years as our laboratories23–29 along with
others22,30–40 have solved nuclear magnetic resonance (NMR)
and crystal structures of single domains of human APOBEC
proteins. These structures are similar as they share the same
secondary structure, including six helices and ﬁve β-strands, and
one HAEx28Cx2–4C zinc-binding motif. We and others have pro-
posed several alternative ssDNA binding surfaces for A3G-CTD
based on NMR and crystal structures of apo-form CTDs23,30,31,35,
yet none of these models are convincing because they lack
atomic-level information of interactions between ssDNA and
protein. Most recently, the crystal structures of A3A in complex
with ssDNA containing a 5ʹ-TC deamination motif have been
reported by us and others29,39. These A3A–ssDNA co-crystal
structures revealed the interactions between A3A and the 5ʹ-TC
motif, and structural similarity with the crystal structure of Sta-
phylococcus aureus tRNA adenosine deaminase (TadA) in com-
plex with RNA29,39.
In this study, we present the co-crystal structure of the A3G-
CTD and ssDNA at 1.86 Å resolution. To overcome A3G-CTD
weak DNA-binding afﬁnity, we generated a catalytically enhanced
variant of A3G-CTD that binds ssDNA stronger than wild-type.
This A3G-CTD variant was co-crystallized with a 9 nucleotides
ssDNA containing a 5ʹ-TCCCA target sequence with all nine
nucleotides well resolved in the structure. The nucleotides within
the 5ʹ-TCCCA target sequence show numerous interactions with
protein, explaining the nucleotide speciﬁcity preferences. Fur-
thermore, the backbone architecture of the protein changed upon
ssDNA binding, enabling the target sequence to ﬁt. These results
provide fundamental insights into the mechanisms by which
APOBEC3s recognize their speciﬁc substrate sequences.
Results
Generation of a Hyperactive A3G-CTD Variant. Although the
CTD of A3G is catalytically active in vitro31,41, detecting strong
ssDNA-binding or purifying stable A3G-CTD–ssDNA complex
has been challenging. To overcome this challenge, we designed
and generated variants that are catalytically more active than the
wild-type protein by introducing amino acid substitutions. The
rationalization was that catalytically hyperactive variants may
have increased afﬁnity for the substrate, while retaining the intact
structure and catalytic mechanism. A similar strategy worked well
for us to generate a soluble A3G-CTD variant, namely CTD-
2K3A, enabling our determination of the solution NMR struc-
ture23. CTD-2K3A contains ﬁve amino acid substitutions
including L234K, C243A, F310K, C321A, and C356A, and these
substitutions alter neither catalytic activity, structure, nor HIV-1
restriction function, but increased solubility23,25. Starting from
CTD-2K3A, ﬁve additional substitutions were made, including
P200A, N236A, P247K, Q318K, and Q322A. To increase the
basicity of the region near the active site, we introduced lysine
residues in loop3 and loop7; P247K and Q318K were chosen as
they enhanced catalytic activity. Those lysine substitutions were
combined with the other three substitutions, which we previously
showed to increase catalytic activity23. This variant, hereafter
called CTD2, spans residues 191–384 of A3G, and contains
P200A, L234K, N236A, C243A, P247K, F310K, Q318K, C321A,
Q322A, and C356A substitutions (Fig. 1a).
The initial reaction speed of deamination of CTD2 was
compared with that of wild-type A3G-CTD using a real-time
NMR deamination assay we and others have previously used for
enzyme kinetics analysis of A3G-CTD31,41. The 9 nucleotides
ssDNA 5ʹ-AATCCCAAA was used for the deamination assay,
which contains the 5ʹ-TCCCA target sequence. 5ʹ-TCCCA is an
optimized target sequence for A3G-CTD41, and Yu et al. reported
that 5ʹ-CCCA is the preferential deamination sequence found in
the minus strand of the HIV-1 genome14. Representative
NMR spectra (Supplementary Fig. 1a), illustrate CTD2 deami-
nates the 3ʹ C in the 5ʹ-TCCCA target sequence ﬁrst, then the
middle C is deaminated, but the 5ʹ TC was not acted upon
by CTD2 as expected based on the preference of wild-type
A3G31,41. Indeed, the initial reaction speed was 20 times faster at
pH 7.5 with 6.9 ± 0.2 reaction min−1 for CTD2 (red) and
0.3 ± 0.1 reaction min−1 for wild-type A3G-CTD (black) (Fig. 1b).
This catalytic activity also increased at lower pH 6.5 (Supple-
mentary Fig. 1b) as we previously observed for A3G-CTD41 with
10.8 ± 0.3 reaction min−1 and 0.5 ± 0.1 reaction min−1 for CTD2
and A3G-CTD, respectively, suggesting that CTD2 retains the
wild-type catalytic mechanism while increasing the reaction
speed.
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Since CTD2 exhibited greater catalytic activity than A3G-CTD
(Fig. 1b), we tested whether it also exhibited increased binding
afﬁnity for ssDNA to the catalytically inactive E259A variant; this
construct will be referred to CTD2*. The 9 nucleotide substrate
ssDNA 5ʹ-AATCCCAAA was labeled with 6-FAM modiﬁcation
at the 3ʹ-end for electrophoretic mobility shift assay (EMSA).
Competitions with a non-speciﬁc (5ʹ-AAAAAAAAA) or a
speciﬁc (5ʹ-AATCCCAAA) negative control ssDNA (ﬂuorescent
unprobed) show that CTD2* speciﬁcally binds the substrate
ssDNA (Fig. 1c). The afﬁnity of CTD2* to the 9nt substrate
ssDNA was further investigated by using microscale thermo-
phoresis (MST)42. The apparent dissociation constant, Kd, for the
CTD2* was determined to be 55 ± 12 μM (Fig. 1d). An EMSA
experiment of A3G-CTD for binding the same 9nt substrate
ssDNA shows signiﬁcantly weaker afﬁnity than CTD2* as only a
faint shifted band observed with 160 µM of A3G-CTD (Supple-
mentary Fig. 1d), which is consistent with the observations
previously reported by other laboratories30,31. As expected from
our previous studies41,43, CTD2* appeared to have signiﬁcantly
less afﬁnity to 5ʹ-TCCdeoxy-UA (the ﬁrst product) and 5ʹ-
TCdeoxy-Udeoxy-UA (ﬁnal product) because Kd values for 9nt
ssDNAs containing these product sequences were determined to
be 150 ± 30 μM and 5.2 ± 0.8 mM, respectively (Supplementary
Fig. 1c). Furthermore, we tested CTD2* for binding the 9nt RNA
containing a target sequence 5′-rArArUrCrCrCrArArA, and Kd
was determined to be 1.5 ± 0.5 mM. Collectively, EMSA and MST
experiments clearly indicate that CTD2* speciﬁcally binds the 5ʹ-
TCCCA target DNA sequence with high afﬁnity, making this
enzyme potentially amenable for structural studies.
To test whether full-length A3G containing wild-type NTD
and CTD2 (NTD-CTD2) retained antiviral activity in vivo, we
prepared HIV virus with increasing amounts of wild-type FLAG-
A3G or FLAG-NTD-CTD2 in the presence or absence of HIV-1
Vif. Both FLAG-A3G and FLAG-NTD-CTD2 were functionally
recognized by Vif and degraded as shown by the absence of A3G
protein in the Vif+ lanes (Fig. 2a). As expected, neither FLAG-
A3G nor FLAG-NTD-CTD2 blocked the infectivity of virus
prepared in the presence of Vif in a single cycle replication assay
(Fig. 2b). However, FLAG-A3G or FLAG-NTD-CTD2 potently
inhibited viral infectivity when the HIV virus was prepared in the
absence of Vif (Fig. 2c), and to similar extents when measuring
comparable FLAG-A3G or FLAG-NTD-CTD2 protein expression
levels from the producer cells (Fig. 2a) (t-test, p > 0.3).
Introduction of mutation E259A into FLAG-NTD-CTD2 (and
FLAG-A3G), which abolishes a critical catalytic glutamate needed
for deaminase activity, restored infectivity in the absence of Vif
indicating that inhibition of HIV-1 replication by FLAG-NTD-
CTD2 is largely deaminase-dependent (Supplementary Fig. 2a, b
and c). Furthermore, no signiﬁcant differences in viral infectiv-
ities were observed for virions encapsidating similar levels of
FLAG-A3G or FLAG-NTD-CTD2 (t-test, p > 0.3) (Supplemen-
tary Fig. 2d and 2e). Overall, these data conﬁrm that the full-
length NTD-CTD2 blocks HIV-1 replication as potently as
wild-type A3G.
Co-crystal Structure of CTD2* and ssDNA. The catalytically
inactive CTD2 (CTD2*) was co-crystallized with the 9nt ssDNA
containing a 5ʹ-TCCCA target sequence (5ʹ-AATCCCAAA). The
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Fig. 1 Generation of a hyperactive A3G-CTD variant. a Amino acid residues of wild-type A3G-CTD and the catalytically hyper-active variant, namely CTD2,
are aligned. 2K3A substitutions (L234K, C243A, F310K, C321A, and C356A) are colored green, and the additional ﬁve substitutions (P200A, N236A,
P247K, Q318K, and Q322A) are colored orange. b Real-time NMR deamination assay. The product (5ʹ-AATCCdeoxy-UAAA) concentration as a function of
reaction time is plotted for CTD2 (red dots) and wild-type A3G-CTD (black dots) deamination at pH 7.5 with 200 nM protein and 200 µM 5ʹ-
AATCCCAAA substrate. For CTD2, the ﬁrst reaction reached completion within 5 h, and the second deamination (5ʹ-AATCCdeoxy-UAAA to 5ʹ-
AATCdeoxy-Udeoxy-UAAA) started, thus decreasing the concentration of the initial product. c EMSA for binding of CTD2* to the 9nt ssDNA
(5′-AATCCCAAA-6-FAM). CTD2*-DNA indicates position of the CTD2*–ssDNA complex, and free DNA indicates the position of protein-free ssDNA.
Fluorescent-unprobed 9nt polyA (5′-AAAAAAAAA) or ﬂuorescent-unprobed 9nt ssDNA (5′-AATCCCAAA) were added with incremental amounts in
lanes 3 (25 nM), 4 (250 nM), and 5 (2500 nM) or 7 (25 nM), 8 (250 nM), and 9 (2500 nM), respectively. Uncropped gel is shown in Supplementary
Fig. 5. d Each dot represents microscale thermophoresis (MST) measurement of a mixture containing ﬂuorescent-labeled CTD2* (50 nM) and the 9nt
ssDNA 5ʹ-AATCCCAAA at various concentrations including 0.12 µM, 0.24 µM, 0.48 µM, 0.97 µM, 1.95 µM, 3.90 µM, 7.81 µM, 15.62 µM, 31.25 µM,
62.5 µM, 125 µM, 250 µM, 500 µM, 1 mM, 2mM, and 4mM. Three independent MST experiments were performed, and bars of data points represent
standard error of n= 3 measurements
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co-crystal structure of CTD2* and ssDNA was determined to
1.86 Å resolution in the P21 space group by molecular replace-
ment using our previously determined structure of apo-CTD-
2K3A (PDB ID: 3IR2)25 (Fig. 3a). The ﬁnal reﬁnement of the
structure resulted in R-work/R-free of 0.18/0.21, respectively
(Table 1). There was a single CTD2*–ssDNA complex in the
asymmetric unit. The overall protein backbone structure did not
change signiﬁcantly from the backbone structures of apo-CTD-
2K3A and A3A bound to ssDNA as indicated by the pairwise root
mean square (rms) deviation, which is1.6 Å for both pairs
including ssDNA-bound CTD2* with apo-CTD-2K3A and DNA-
bound CTD2* with ssDNA-bound A3A.
All nine nucleotides of ssDNA are well-ordered in the electron
density (Fig. 3a). The interface between protein and ssDNA
involves all ﬁve nucleotides of the 5′-TCCCA target sequence,
and approximately 800 Å2 of surface area on ssDNA is buried in
the interface with CTD2*. This is a signiﬁcantly larger area than
that found in an A3A–ssDNA complex where approximately 620
Å2 of surface area on ssDNA was buried in the protein–DNA
interface29. Although more extended at both 5ʹ- and 3ʹ-ends, the
phosphate backbone of the ssDNA adopted a curved shape that is
similar to the shape of ssDNAs we and others observed in the co-
crystal structures of A3A–ssDNA29,39 and TadA–RNA44.
Remarkably, all ﬁve nucleotides in the target sequence interact
with the protein in the co-crystal structure (Fig. 3b). As others
have done, in the target sequence, nucleotides are numbered with
the target cytidine at position 0 such as 5′-T−3C−2C−1C0A+1.
Therefore, we describe here protein–DNA interactions for each
nucleotide in the following sections.
The most remarkable interaction involving T−3 is the π–π
stacking with W211 (Fig. 3c). T−3 also interacts with the
following nucleotide C−2 by forming a hydrogen bond between
the 5ʹ-phosphate group of T−3 and the pyrimidine amino group
of C−2. The Watson–Crick face of T−3 does not interact with the
protein, whereas it forms a base pair with A+3 of the ssDNA in a
neighboring asymmetric unit (Supplementary Fig. 3).
The nucleobase type of C−2 is recognized by the protein since
Watson–Crick face of C−2 forms water-mediated hydrogen bonds
between the pyrimidine carbonyl group and the mainchain amino
proton of D316 as well as the guanidino group of R374 (Fig. 3c).
In addition, the pyrimidine N3 atom of C−2 forms a hydrogen
bond through an ordered water with the carboxyl group of D316
(Fig. 3c). Furthermore, the C−2 pyrimidine ring has a
hydrophobic interaction with the indole ring of W211 (Fig. 3c),
which creates a spatial restraint, favoring a pyrimidine nucleotide
in this position.
Sugar pucker of nucleotides plays a key role in shaping the
structure of DNA and RNA strands. The deoxy-ribose of C−2 has
a C3ʹ-endo conformation, whereas all other eight nucleotides of
the CTD2*-bound ssDNA have C2ʹ-endo conformation. This is
signiﬁcant because DNA prefers the C2ʹ-endo in aqueous
solution, whereas RNA is predominantly in the C3ʹ-endo
conformation. The C3ʹ-endo conformation of C−2 brings two
neighboring backbone phosphorus atoms (which belong to C−1
and C−2) in a close contact 5.8 Å, which is a typical distance for
double-stranded RNAs in A-form. This spatial arrangement
enables the 5ʹ-phosphate group of C−2 to form a hydrogen bond
with the guanidino group of R213. Interestingly, R213 is not
conserved in other APOBEC3 proteins, except the charge is
conserved with a lysine in AID, which we further describe in the
Discussion.
The Watson–Crick face of C−1 has three direct interactions
with the protein. The C2 carbonyl group forms a hydrogen bond
with the mainchain amino proton of D317, the N3 atom forms a
hydrogen bond with the mainchain amino proton of Q318K, and
the amino group forms a hydrogen bond with the sidechain
carboxyl group of D316 (Fig. 3d). The sidechain of D317 is also
coordinated by a hydrogen bond formed between the carboxyl
group and the mainchain amino proton of F289. This hydrogen
bond stabilizes the helix3 structure by forming an “N-cap”45 since
F289 is located at the N-terminus of the helix. In addition, Q318K
may provide further support in orienting D317 by interacting
electrostatically as the ε-ammonium group of Q318K is located
within 3.7 Å from the carboxyl group of D317 (Supplementary
Fig. 4). Furthermore, the 5ʹ-phosphate group of C−1 is supported
by two water-mediated hydrogen bonds with the NE2 atom of
H216 and the mainchain amino proton of R215 (Fig. 3d).
We observed electron density that ﬁts a zinc ion (Zn2+)
chelated by H257, C288, C291, and additional density that ﬁts a
water molecule. The target cytosine (C0) is tightly packed under
the Zn2+ ion by stacking aromatic rings with the Zn2+-chelating
residue H257 and forming a T-shaped π–π interaction with Y315
(Fig. 3e). In addition to these π–π interactions, many hydrogen
bonds support the position of target cytosine, including aromatic
ring O2 to the mainchain amino proton of A258, and aromatic
ring N3 to the mainchain amino proton of E259A through an
ordered water molecule. Furthermore, the deoxy-ribose O3ʹ and
O4 atoms form hydrogen bonds with the sidechain amino group
of N244 and the hydroxyl group of T218, respectively, which
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supports the 2′-endo conformation of deoxy-ribose of C0. The 5ʹ-
phosphate group of C0 is well-coordinated by interactions with
the protein as it forms hydrogen bonds with the hydroxyl group
of Y315 and ND1 atom of H216. Two hydrogen bonds provide
key recognition of the amino group of C0, including one formed
with the mainchain carbonyl group of S286, and another
formed with the water molecule coordinated by Zn2+. This
Zn2+-bound water molecule is the key molecule to trigger the
deamination by attacking the C4 position of cytosine18–20. These
C0-interacting residues are conserved in all APOBEC3 proteins
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(except A3F has a serine instead of T218), and we and others have
observed similar interactions in A3A–ssDNA complexes29,39.
Although the CTD2*–ssDNA complex showed that C2ʹ-endo
sugar conformation of the target cytidine is required to ﬁt in the
catalytic pocket, the mechanism by which A3G discriminates
RNA from deamination is not fully understood because the 2ʹ
hydrogen of the target cytidine can be replaced with a hydroxyl
group without signiﬁcant steric hindrance in the CTD2*–ssDNA
complex structure.
The purine ring of A+1 stacks against the H216 imidazole ring
(Fig. 3f). Since histidine forms stronger π–π stacking with a
purine ring than with a pyrimidine ring46, this interaction selects
purines in the +1 position rather than pyrimidines, providing an
explanation for why 5ʹ-CCCA is the preferential deamination
sequence14,41. In addition, the 5ʹ-phosphate group forms water-
mediated hydrogen bonds with the mainchain carbonyl group of
H216 and the sidechain amino group of N244. The
Watson–Crick face of A+1 does not have interaction with protein
as it forms a base pair with A−5 of a neighboring asymmetric unit
(Supplementary Fig. 3).
Overall, CTD2* recognizes 5ʹ-C−2C−1C0 through hydrogen-
bonds formed with their Watson–Crick faces, and T−3 and A+1
by using strong π–π interactions (Fig. 3g). Unusual sugar pucker
of C−2 contributes in shaping the phosphate backbone to ﬁt the
ssDNA-binding site of CTD2*. The movements of CTD2*
residues induced upon the ssDNA-binding will be discussed in
the following section.
Discussion
Since we reported the ﬁrst structure of the catalytic domain of
A3G almost 10 years ago23, structural studies of the A3G-
CTD–ssDNA complex have been hampered by apparently weak
binding of A3G-CTD to ssDNA23,31. We have overcome this
problem by generating a A3G-CTD variant that binds ssDNA
with higher afﬁnity than wild-type. P247K appears to be a key
substitution that contributes to stabilizing the ssDNA-binding of
CTD2* by providing an additional hydrogen bond to a backbone
phosphate group located outside of the target sequence (Supple-
mentary Fig. 4). Furthermore, non-Watson–Crick base pairs
formed between neighboring asymmetric units in the
CTD2*–ssDNA co-crystal may stabilize the crystallization of
the complex (Supplementary Fig. 3). Critically, this highly active
variant in the context of full-length A3G containing wild-type
NTD restricted HIV-1 infection as potently as wild-type A3G in a
Vif-dependent manner (Fig. 2).
A3G strongly prefers a cytidine at the −1 position, whereas
A3A prefers a thymidine for that position. CTD2 and A3A form
hydrogen bonds with the Watson–Crick face of the nucleotide at
the −1 position to provide nucleobase speciﬁcity. For the
CTD2*–ssDNA complex, the Watson–Crick face of C−1 forms
three hydrogen bonds including amino group (NH2) to carboxyl
group of D316, carbonyl group to mainchain amino proton of
D317, and N3 atom to mainchain amino proton of Q318K. If this
cytidine is replaced by a thymidine, N3 and NH2 would be
replaced by NH and CO, respectively, resulting in the loss of two
hydrogen bonds with the protein, which explains why A3G
prefers cytidine over thymidine at the −1 position. Previously,
Rausch et al. showed that N3 and NH2 of cytosine ring of C−1
and C−2 are key for deamination efﬁciency, whereas 5-methyl
deoxy-cytidine at C−1 or C−2 position are tolerated by A3G47.
This ﬁnding is consistent with the CTD2*–ssDNA structure
showing that Watson–Crick faces of C−1 and C−2 interact with
CTD2*, while the C5 positions do not have a contact with the
protein (Fig. 3b). In addition to the recognition of the
Watson–Crick face, the spatial coordination plays an important
role in the recognition of C−1. Figure 4a, b shows a striking
difference between the position of C−1 in the CTD2*–ssDNA
complex and that of T−1 in the A3A–ssDNA complex. Interac-
tions of T−3 and C−2 with CTD2* are important to position C−1
(Fig. 3b, c), whereas the A3A–ssDNA structures did not have
interactions with nucleotides at −2 and −3 positions29,39. A3A
has a tyrosine (Y132) at the corresponding position to D317, and
Fig. 4c shows that C−1 crashes into Y132 when we overlay the
CTD2*–ssDNA structure onto the A3A–ssDNA structure. The
signiﬁcance of D316 and D317 in substrate speciﬁcity of A3G was
originally reported by Holden and co-workers as they showed
that D316R, D317R double substitutions enabled A3G to
Fig. 3 Structure of CTD2* in complex with ssDNA. a The asymmetric unit contains one protein (yellow) and one ssDNA (blue) molecule. A 2Fo–Fc electron
density map contoured at 1σ is shown in cyan around the ssDNA. Zn2+ ion is colored purple. N and C indicate the N- and C-terminal ends of the protein,
respectively. b An enlarged view shows interactions between the 5ʹ-TCCCA target sequence and the protein. Protein is colored yellow, 5ʹ-TCCCA is blue,
and amino acid sidechains interacting with DNA are shown as sticks. c–f Enlarged views show interactions between T−3, C−2, C−1, C0, or A+1 and protein.
C, N, and O atoms are colored yellow, blue, and red, respectively, for amino acid residues of the protein. Atoms in nucleotides are colored blue, navy blue,
red, and orange for C, N, O, and P, respectively. Water molecules are shown as red spheres, and Zn2+ is shown as a purple sphere. Dotted lines indicate
hydrogen bonds. In (c), the double arrow-headed line points to the neighboring backbone phosphorous atoms of C−1 and C−2. In (d), sidechains of F289
and Q318K are not shown. g Summary of the interactions between CTD2* and nucleotides in the 5ʹ-TCCCA target sequence
Table 1 Crystal data collection and reﬁnement statistics
Data collection
Space group P21
Cell dimensions
a, b, c (Å) 47.41, 47.24, 51.56
α, β, γ (°) 90.00, 103.13, 90.00
Resolution (Å) 50.00–1.86 (1.93–1.86)a
Rmerge (%) 8.3 (32.8)
Rmeas (%) 8.9 (35.3)
Rpim (%) 3.3 (13.0)
I/σI 24.1 (6.3)
CC1/2 0.989 (0.957)
Completeness (%) 100.00 (100.00)
Redundancy 7.5 (7.3)
Reﬁnement
Resolution (Å) 38.6–1.86 (1.92–1.86)
No. of reﬂections 18,843 (1812)
Rwork/Rfree (%) 17.89/21.11
No. of atoms 1893
Protein 1553
DNA 179
Ligand (GOL)/Ion (Zn2+) 6/1
Water 154
B-factor
Average B-factors (Å2) 33.9
Protein/DNA 33.6
Ligand/ion 43.3
Water 36.6
rms deviations
Bond lengths (Å) 0.006
Bond angles (°) 0.76
aValues in parentheses are for the highest-resolution shell
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deaminate middle C and 3′ C of a 5ʹ-CCC motif at the same
reaction speed30, whereas the wildtype A3G-CTD prefers 3ʹ C to
the middle C by 45-fold41. Another group showed that D317Y
substitution changed A3G substrate preference to 5′-TC that is
the A3A preferred target sequence48. The co-crystal structure of
CTD2* and ssDNA showed how D316 and D317 are involved in
the recognition of C−1. Overall, spatial coordination as well as the
interaction with the Watson–Crick face are critical for speciﬁc
recognition of C−1.
We and others have reported structures of A3G-CTD wild-
type30,31,35, and a soluble variant, namely CTD-2K3A23,25. None
of these structures were complexed with ssDNA, and we chose
our previous crystal structure of CTD-2K3A, solved at 2.25 Å
resolution (PDB ID# 3IR225), as a representative of apo-form
CTD for structural comparison with ssDNA-bound CTD2*.
Superimposition of structures of ssDNA-bound CTD2* (yellow)
and apo-CTD-2K3A (gray) (Fig. 5a) reveals that even with the
additional substitutions in CTD2* the backbone structures are
essentially unchanged. Regions that are changed include loops 1,
3, and 7, which are intrinsically dynamic in solution as shown in
NMR structures of CTD-2K3A23,24. Loops 1 and 7 contain amino
acid residues, which form numerous interactions with ssDNA;
therefore, the structural changes were likely induced upon ssDNA
binding.
Loop1 migrates toward loop7 upon ssDNA binding, with
W211 demonstrating the biggest change with its Cα atom moved
by 3.9 Å from the position found in the apo-form CTD-2K3A
(Fig. 5b). This backbone change enables W211 to have π–π
stacking interaction with T−3. The sidechain of H216 showed a
big rotamer change, enabling π–π stacking with A+1 (Fig. 5b).
These π–π interactions set both 5ʹ- and 3ʹ-ends of the 5ʹ-TCCCA
target sequence to the rim of the DNA-binding groove formed by
loop1 of CTD2*. This rim is clearly visible by sidechains of W211,
R213, and H216 in the surface representation of CTD2* (Fig. 5c).
This loop1 rim interacts with the phosphate backbone of ssDNA,
whereas loop7 faces nucleobases as depicted by the sidechains of
Y315 and D316 (Fig. 5c). Residues in loop7, including Y315,
D316, and D317, also alter mainchain atom positions and side-
chain rotamers upon ssDNA-binding (Fig. 5b). D317 signiﬁcantly
changed its mainchain position as its Cα atom moved 3.0 Å from
the position found in the apo-form CTD-2K3A structure
(Fig. 5b). These rearrangements of backbone atoms of the loop7
residues are particularly important for recognition of C−1, as
mainchain amino protons form two hydrogen bonds with the
Watson–Crick face of C−1 (Fig. 3d). This dynamic property of
CTD2* is a remarkable difference compared to A3A, which did
not show signiﬁcant changes in mainchain atom positions upon
ssDNA-binding. For A3A, only the sidechains of R28 and H29
(R215 and H216 in CTD2, respectively) in loop1, and Y132 (Y315
in CTD2) in loop7 changes their rotamers29,39.
Most recently, Ziegler et al. published a structure of A3G-CTD
bound to an adenine nucleotide49. In the A3G-CTD–adenine
complex structure, the adenine nucleotide binds in the space that
is similar to the T−1 position found in the A3A–ssDNA com-
plexes29,39. Since C−1 in the CTD2*–ssDNA complex does not
occupy the T−1 position (Fig. 4c), the protein–DNA interaction
found in the A3G-CTD–adenine complex49 is different from the
enzyme–substrate interaction revealed in our study. Ziegler et al.
suggested that the A3G-CTD–adenine structure shows a non-
speciﬁc interaction by which A3G-CTD scans ssDNA sequence49.
Interestingly, W211 rearranged its position to interact with the
bound adenine49, which may imply that W211 is important in the
interaction with non-speciﬁc DNA as well as the target sequence.
As mentioned in the previous section, P247K is the only
residue in loop3, which interacts with ssDNA, and the interaction
likely contributes in changing the loop3 position (Supplementary
Fig. 4a). In addition, other loop3 residues including E254 and
R256 form hydrogen bonds with Q293 (helix3) and E323 (helix4)
of a neighboring asymmetric unit, respectively, which support the
position of loop3 and concurrently aids crystal formation.
Noteworthy, the substitutions introduced to CTD2 did not
change the structure of A3G-CTD as shown in the superimposed
structures of CTD2* (this study) and wild-type A3G-CTD (PDB
ID: 4ROV)35 (Supplementary Fig. 4b). CTD2* and 4ROV struc-
tures are well superimposed as indicated by the pairwise rms
deviation, which is 0.9 Å.
We have previously found that A3G-CTD increases its catalytic
activity at lower pH, and H216 plays a key role in this pH
dependence41. Alanine mutation of this residue abolished cata-
lytic activity, whereas arginine mutation kept catalytic activity but
lost the pH dependency, suggesting that positive charge and/or
formation of hydrogen bonds of this residue are important for
substrate binding41. The CTD2*–ssDNA co-crystal structure
indicates that protonation of the imidazole ring enables the for-
mation of two hydrogen bonds with the 5ʹ-phosphate groups of
C0 and C−1. H216 is conserved only in A3G and A3A among
human APOBEC3 proteins, and similar interactions between the
histidine and nucleotides at −1 (T−1) and 0 (C0) positions have
been observed in co-crystal structures of A3A and ssDNA29,39.
These conserved interactions involving histidines provide an
explanation for similar pH dependency of catalytic speeds of A3A
and A3G41,50.
Until this study, we have been puzzled how W211 contributes
to catalysis as this residue is spatially far from the catalytic Zn2+
ion yet alanine substitution of W211 results in nearly complete
loss of catalytic activity23. Moreover, we observe large chemical
shift changes for the indole amino proton of W211 upon mixing
with ssDNAs23,51. Interestingly, while W211 is not conserved in
other members of human APOBEC3 proteins, tryptophan is
conserved in AID. AID is a member of the human APOBEC
a b c
C0 C0
C–1
T–1
Y315 Y130
Y132
D317
Y132
C–1
D316
D131
Fig. 4 Comparison of CTD2* and A3A recognition of the nucleotide at −1 position. a Interaction of cytidine at −1 position (C−1, blue) with residues of
CTD2* (yellow) in the CTD2*–ssDNA complex (this study). b Interaction of thymidine at −1 position (T−1, cyan) with residues of A3A (gray) in the
A3A–ssDNA complex (PDB ID: 5KEG). c Superimposition of the CTD2*–ssDNA and A3A–ssDNA complexes showing nucleotides at the −1 position and
their interacting residues from both structures
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family, that plays important roles in antibody diversiﬁcation and
triggers both class switch recombination and somatic hypermu-
tation52–54. Qiao et al. recently published structures of the human
AID protein co-crystalized with dCMP, cacodylic acid or cytidine
(PDB ID# 5W0U, 5W0R, 5W1C, respectively), and proposed a
“substrate channel” composed by loop1 and loop7 of AID40. AID
appears to recognize long target sequences, similar to A3G
recognition of a ﬁve nucleotide target sequence, and AID has
nucleotide preferences in −2, −1, 0, and +1 positions55,56. Based
on the CTD2*–ssDNA complex, AID likely uses the tryptophan
residue corresponding to W211 for π–π stacking with the
nucleotide at the −3 position, and supports speciﬁc recognition of
the nucleotides at −2 and −1 positions in a manner similar to
CTD2* use of W211. In addition, conservation of R213 of CTD2*
as a lysine in AID suggests the similar use of the lysine for
interaction with 5ʹ-phosphate group of the nucleotide at −2
position. Further experimental data and structures are necessary
to elucidate the ssDNA interactions of AID.
This structure of the CTD2*–ssDNA complex reveals the
mechanism at atomic-level resolution by which the catalytic
domain of A3G uniquely binds substrate ssDNA. Fundamental
knowledge of this complex can guide the design of molecular-
based therapeutics for AIDS by modulating A3G catalytic func-
tion. In addition, recently, Komor et al. showed that an APOBEC
deaminase tethered to catalytically dead Cas9 can mutate DNA in
a programmable manner, offering a new strategy for “gene
editing”57. The CTD2 variant may be a better tool for “base
editing” because it is more soluble, binds ssDNA stronger and
catalyzes deamination faster than wild-type A3G-CTD.
Methods
Protein Expression and Puriﬁcation. The CTD2 variant of human A3G CTD
(residue 191–384) and its inactive variant CTD2* were expressed from pGEX6P-1
expression plasmid [P247K was introduced by synthesizing cDNA (GenScript),
and the primer sequences used for E259A and Q318K substitutions are listed in
Supplementary Table 1] with Glutathione S-transferase (GST) tag (crystallography,
EMSA, and real-time NMR deamination assay) for GST puriﬁcation or from pET-
28a plasmid with poly-Histidine tag (MST assay) for Ni-NTA puriﬁcation in E. coli
BL21(DE3) cells (Invitrogen). Cells were grown in LB media at 37 °C until reaching
an optical density of 0.5–0.6 at 600 nm. Then, temperature was reduced to 17 °C
and protein expression was induced for 18 h with 0.2 mM isopropyl β-D-1-
thiogalactopyranoside (IPTG).
All the steps for protein puriﬁcation were performed at 4 °C. E. coli cells were
harvested by centrifugation and re-suspended in lysis buffer (either 50 mM sodium
phosphate pH 7.3, 150 mM NaCl, 25 µM ZnCl2, 2 mM DTT, and 0.002% Tween-20
for GST puriﬁcation or 50 mM sodium phosphate pH 7.3, 150 mM NaCl, 50 μM
ZnCl2, 1 mM DTT, and 0.002% Tween-20 for Ni-NTA puriﬁcation) and EDTA-
free protease inhibitor cocktail (Roche, Basel, Switzerland). The suspended cells
were disrupted by sonication and then cell debris were separated by centrifugation
at 48,384g for 30 min. Supernatant containing desired protein was applied to either
Glutathione-Sepharose resin (GE Healthcare Life Science) for GST puriﬁcation or
Ni-NTA Agarose resin (QIAGEN) for Ni-NTA puriﬁcation, equilibrated with lysis
buffer and agitated for about 2 h.
For GST puriﬁcation, protein-bound resin was washed with Pre-Scission
Protease cleavage buffer (50 mM sodium phosphate, pH 7.5, 100 mM NaCl, 10 µM
ZnCl2, 2 mM DTT, and 0.002% Tween-20) and incubated with Pre-Scission
H216
R213
W211
Y315
D316
D317
Loop7
Loop1
a b
H216
W211
R213
D316
Y315
A+1
T–3
C0
C–1C–2
c
C
N
Loop7
Loop1
Loop3
Fig. 5 Comparison of structures of CTD2* with apo-CTD-2K3A. Proteins are in the same orientation in all three ﬁgures. a Superimposed yellow and gray
cartoons show structural features of CTD2* (this study) and CTD-2K3A (PDB ID# 3IR2), respectively. W211, R213, H216, Y315, D316, and D317 sidechains
of CTD2* are shown in sticks. Zn2+ ion is shown as a purple sphere. ssDNA is not shown. b An enlarged view of (a) that shows the repositioning of the
critical residues W211, R213, and H216 of loop1, and Y315, D316, and D317 of loop7. Double headed arrows point to positions of Cα atoms of W211 and
D317. c Surface representation of ssDNA-bound CTD2* (this study). Locations of the loop1 and loop7 residues are labeled except D317 because D317 is not
seen on the surface. The 5ʹ-TCCCA target sequence is shown as sticks, and C, N, O, and P atoms are colored blue, dark blue, red, and orange, respectively
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protease (GE Healthcare Life Science) for 18 h. The supernatant containing the
cleaved protein was separated from the resin by centrifugation and loaded on to
HiLoad 16/600 Superdex 75 gel ﬁltration column (GE Healthcare Life Science)
equilibrated with 20 mM Bis–Tris (pH 6.5), 100 mM NaCl, 1 mM DTT, 0.01 mM
ZnCl2, and 0.002% Tween-20.
For Ni-NTA puriﬁcation, protein-bound resin was washed with 50 mM sodium
phosphate, pH 7.3, 1 M NaCl, 25 µM ZnCl2, 1 or 2 mM DTT, and 0.002% Tween-
20. Protein was eluted from resin in buffer containing 400 mM imidazole, 50 mM
sodium phosphate, pH 7.3, 100 mM NaCl, 1 mM DTT, and 0.002% Tween-20.
Eluted protein was loaded on to HiLoad 16/600 Superdex 75 gel ﬁltration column
equilibrated with 20 mM Bis–Tris pH 6.5, 100 mM NaCl, 1 mM DTT, 0.002%
Tween-20, and 20 μM ZnCl2. For both GST and Ni-NTA puriﬁcation, protein
purity was analyzed by SDS-PAGE.
Crystal Growth and Data Collection. Samples used for crystallization contained
about 9.5 mg/ml (415 µM) CTD2* and a 50% molar excess of ssDNA in 20 mM
Bis–Tris pH 6.5, 100 mM NaCl, 1 mM DTT, 10 µM ZnCl2, and 0.002% Tween-20.
The 9 nucleotide ssDNA, 5ʹ-AATCCCAAA, was obtained from Integrated DNA
Technologies (IDT; Coralville, IA). Initial crystallization condition was identiﬁed
using JBScrene Nuc-Pro from MiTeGen. Crystals were grown at 4 °C, by sitting
drop vapor diffusion method over a 65 µl reservoir of 20% W/V PEG 6000, 50 mM
di-sodium L-malate; pH 5.0 and 30 mM CaCl2 in a sitting drop 2 well crystal-
lization plate from Molecular Dimension. Drops were set up by mixing 0.3 µl of
CTD2*–ssDNA complex and 0.3 µl of reservoir solution using a robot, Mosquito
Crystal from TTP Labtech. Crystals appeared after 1 week. Crystals grown at 4 °C
were melted at room temperature, and exactly similar crystal setup at 20 °C did not
produce any crystal.
Crystals were cryoprotected using reservoir solution containing 20% v/v
glycerol and ﬂash frozen in liquid nitrogen. X-ray diffraction data were collected at
Southeast Regional Collaborative Access Team (SER-CAT) 22-ID beamline at the
Advanced Photon Source, Argonne National Laboratory. The crystals belong to the
space group P21. The collected intensities were indexed, integrated, and scaled
using HKL200058.
Structure Determination and Analysis. The structure was solved at 1.86 Å
resolution by molecular replacement using the program Phaser59 and a previously
determined structure of A3G-2K3A (PDB ID code 3IR2, chain B was removed) as
search model25. Model building of the protein and bound DNA and reﬁnements
were manually performed using the programs Coot60 and Phenix61,62, respectively.
The ﬁrst 3 residues (Glu–Ile–Leu) and the last residue (Asn) were not modeled due
to lack of electron density. Due to the presence of extra positive density, Ser-368
and Ser-372 were modeled in two alternative conformations. The ﬁnal model was
reﬁned to Rwork/Rfree values of 0.18/0.21 and was validated with the PDB validation
tool and Molprobity63. Statistics of Ramachandran analysis yielded 97.87% of the
residues in the favored regions and 2.13% were found in the allowed regions. None
of the residues were found in disallowed regions. Pairwise rms deviation between
CTD-2K3A and ssDNA-bound CTD2* and between ssDNA-bound A3A and
ssDNA-bound CTD2* were calculated using Doli64. Figures of structure models
were generated by PyMOL65.
Real-time NMR Deamination Assay. We determined initial rates of deamination
reaction by using 1H NMR spectra. A 9nt ssDNA substrate (IDT), 5ʹ-AATCC-
CAAA, was used to determine the reaction rate. NMR spectra were acquired at
25 °C on Bruker NMR spectrometers operating at 1H Larmor frequencies of 600
and 800MHz. NMR samples contained 5% deuterium oxide with 200 nM protein,
200 µM ssDNA substrate, 100 mM NaCl, 0.002% Tween 20, 1 mM DTT, 10 µM
ZnCl2, and also included 50 mM sodium phosphate adjusted to pH 7.5. The
concentration of deamination product (5ʹ-AATCCdeoxy-UAAA) was determined
from integration of the H5 uracil proton peaks at 5.60 ppm. A series of 1H spectra
were measured and the product concentrations as a function of the reaction times
were used to determine the initial rate via linear regression.
EMSA. For EMSA, we used a 9nt ssDNA with 6-FAM at the 3ʹ end 5ʹ-
AATCCCAAA-FAM (IDT), and binding buffer containing 20 mM Bis–Tris pH
6.5, 100 mM NaCl, 1 mM DTT, 10 µM ZnCl2, and 0.002% Tween 20 detergent. To
test the speciﬁc DNA binding, we performed competition assays with ﬂuorescent-
unprobed ssDNAs including 5ʹ-AAAAAAAAA and 5ʹ-AATCCCAAA, as a non-
speciﬁc and a speciﬁc ssDNA, respectively. Binding reactions were performed
in 50 µl by mixing the 6-FAM-labeled ssDNA (5ʹ-AATCCCAAA-FAM) with
CTD2* at 10 nM and 15 μM concentration, respectively. A competitor ssDNA was
added with incremental amounts, 0, 25, 250, and 2500 nM. Reaction mixtures were
incubated for 1 h at room temperature. Samples (10 μl) were mixed with Novex Hi-
Density TBE sample buffer (5× loading dye from Invitrogen) and loaded onto a
4–12% precast TBE gel (Invitrogen) and run with 0.5× TBE buffer for 60 min at
100 V at 4 °C. Gels were imaged by using a Typhoon imager (GE Healthcare Life
Sciences) using the blue-excitation (488 nm) ﬂuorescence mode.
Microscale Thermophoresis Assay. The binding afﬁnity of puriﬁed CTD2* to
9nt ssDNA 5ʹ-AATCCCAAA (IDT) was measured using Monolith NT.115 (Nano
Temper Technologies, GmbH, Munich, Germany)42. RED-tris-NTA ﬂuorescent
dye solution was prepared at 100 nM in the MST buffer (20 mM Bis–Tris pH 6.5,
100 mM NaCl, 1 mM DTT, 0.002% Tween 20, 20 μM ZnCl2). CTD2* was mixed
with dye at ﬁnal concentration of 100 nM and incubated for 30 min at room
temperature followed by centrifugation at 15,000g for 10 min. The ssDNA was
prepared to a stock concentration of 8 mM in the MST buffer. To determine the
binding afﬁnity, 10 μl of ssDNA solution at 16 different concentrations, ranging
from 8mM to 0.244 µM, were prepared in LoBind centrifuge tubes (Fisher Sci-
entiﬁc), then 10 μl of ﬂuorescent-labeled CTD2* solution was added to each tube.
The mixtures were incubated at 4 °C to reach equilibrium. Each incubated solution
was loaded into a Nano Temper MST premium coated capillary. The measurement
was performed at room temperature using 40% LED power and 20% MST power.
The experiment was repeated three times and data analysis was carried out using
Nano Temper analysis software (MO afﬁnity).
HIV-1 Restriction Assay. The plasmids in this study are designated
with a “p” while the names of viruses and proviruses generated from these plasmids
are not. pHCMV-G expresses the G glycoprotein of vesicular stomatitis virus
(VSV-G)66. pHDV-EGFP is an HIV-1 derived vector that expresses HIV-1 Gag-Pol
and enhanced green ﬂuorescent protein (EGFP) but does not express Env, Vif, Vpr,
Vpu, or Nef67. pVif-HA is a codon-optimized HIV-1 Vif expressing a C-terminal
HA epitope tag68. pFLAG-A3G expresses wild-type A3G with an N-terminal
FLAG epitope tag69. To create pFLAG-NTD-CTD2, unique EcoRI and XbaI
cloning sites from pFLAG-A3G were used to subclone a codon-optimized A3G
containing solubility mutations 2K3A (L234K+ C243A+ F310K+ C321A+
C356A)23 and mutations P199A, P200A, N236A, P247K, Q318K, and Q322A. To
create pFLAG-A3G-E259A and pFLAG-NTD-CTD2-E259A, plasmids
pFLAG-A3G and pFLAG-NTD-CTD2 were subjected to site-directed mutagenesis
to introduce E259A (Quick Change Lightning Site-Directed Mutagenesis Kit,
Agilent Technologies). All ﬁnal plasmids were conﬁrmed by sequencing
(Macrogen).
Human embryonic kidney 293T cells (American Type Culture Collection) and
TZM-bl cells (obtained through the NIH AIDS Reagent Program [Cat. No. 8129],
Division of AIDS, NIAID, NIH: TZM-bl from Dr. John C. Kappes, Dr. Xiaoyun
Wu, and Tranzyme Inc.70) were grown in Dulbecco’s modiﬁed Eagle’s
medium (DMEM) supplemented with 10% fetal calf serum (HyClone) and
1% penicillin–streptomycin stock (penicillin 50 U/ml and streptomycin 50 μg/ml,
ﬁnal concentration; Gibco). TZM-bl cells contain a HIV-1 tat-inducible luciferase
reporter gene that correlates with HIV-1 infectivity. All cells were maintained in
humidiﬁed 37 °C incubators with 5% CO2.
All transfections were performed using LT1 reagent (Mirus) according to
manufacturer’s instructions. To generate virus for infection, in brief, 293T cells
were transfected with pHDV-EGFP (1 μg), with or without pVif-HA (2.5 μg),
pHCMV-G (0.25 μg), and variable concentrations of pFLAG-A3G or pFLAG-
NTD-CTD2 (21, 42, 84, 170, or 340 ng). To maintain equivalent DNA amounts in
the transfection mix, pcDNA3.1 was substituted as needed. Forty-eight hours post
infection, virus was harvested, ﬁltered with 0.45-μM ﬁlters, and stored at −80 °C.
Capsid p24 measurements were analyzed using the HIV-1 p24 ELISA Kit
(XpressBio) according to manufacturer’s instructions. Normalized p24 was used to
infect 4000 TZM-bl cells in a 96-well plate, and 48 h post infection, luciferase
activity was measured using a 96-well luminometer (LUMIstar Galaxy, BMG
LABTECH). Data were plotted as the percent inhibition of luciferase activity versus
the no A3G control. For some experiments, portions of the viral supernatant were
spun through a 20% sucrose cushion (15,000 rpm, 2 h, 4 °C, in a Sorvall WX80+
ultracentrifuge) and concentrated 10-fold and used in experiments to determine
virion encapsidation of FLAG-A3G and FLAG-NTD-CTD2 by western blotting
analysis.
Cell lysates were made using CelLytic M (Sigma) solution containing Protease
Inhibitor Cocktail (Roche), followed by a 10 min, 10,000×g spin to remove cellular
debris. The cell lysates were mixed with NuPAGE LDS sample buffer (Invitrogen)
containing β-mercaptoethanol and heated for 5 min at 95 °C. Samples were
analyzed on 4–20% Tris-Glycine Gels (Invitrogen) using standard western blotting
techniques. Proteins were detected with primary antibodies as follows: FLAG-A3G
or FLAG-NTD-CTD2 (rabbit anti-FLAG polyclonal antibody, 1:5000 dilution,
Sigma #F7425); Vif-HA (mouse anti-HA monoclonal antibody, 1:5000
dilution, Sigma #H3663); α-tubulin (mouse anti-α-tubulin antibody, 1:10,000
dilution, Sigma #T9026); Antibody against HIV-1 p24 (monoclonal,
1:10,000 dilution) was obtained through the NIH AIDS Reagent Program, Division
of AIDS, NIAID, NIH: HIV-1 p24 Gag Monoclonal (#24-3) from Dr. Michael
Malim (catalog #6458)71. An IRDye 800CW-labeled goat anti-rabbit secondary
antibody (LI-COR #926-32211) was used at a 1:10,000 dilution to detect rabbit
primary antibodies and an IRDye 680-labeled goat anti-mouse secondary antibody
(LI-COR #926-68070) was used at a 1:10,000 dilution to detect mouse primary
antibodies. Protein bands were visualized and quantiﬁed using an Odyssey Infrared
Imaging System (LI-COR). Uncropped western blots are shown in Supplementary
Figs. 6, 7, and 8.
Data Availability. Atomic coordinates and structural factors for the reported
crystal structure have been deposited in the Protein Data Bank under the accession
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number 6BUX. Other data are available from the corresponding author upon
reasonable request.
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